NRX Pharmaceuticals, Inc. Proceeds from Notes Payable
NRX Pharmaceuticals, Inc. (NRXP) reported Proceeds from Notes Payable of $155.21 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-08-12
- NRX Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2021-03-31 was $155.21K, a 61.26% increase year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2020-12-31 was -$9.52K, a 113.45% decline year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2020-09-30 was $9.68K, a 88.59% decline year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2020-06-30 was $523.60K.
- NRX Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2020 was $620.00K, a 26.68% decline from fiscal 2019.
- NRX Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2019 was $845.62K, a 22.55% increase from fiscal 2018.
- NRX Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2018 was $690.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 6 month as first filed | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 9 month as first filed | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | $155.21K 10-Q · filed 2021-05-21 | $145.68K derived: sum of 2 quarters · filed 2022-03-31 | $155.36K derived: sum of 3 quarters · filed 2022-08-12 | $678.96K derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | -$9.52K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $158.00 derived: sum of 2 quarters · filed 2022-08-12 | $523.75K derived: sum of 3 quarters · filed 2022-08-12 | $620.00K 10-K · filed 2022-03-31 | $274.27K 10-K · filed 2021-04-01 | ||
| 2020-09-30 | $9.68K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $533.28K derived: sum of 2 quarters · filed 2022-08-12 | $629.52K 10-Q/A · filed 2022-08-12 | $157.68K 10-Q · filed 2020-11-16 | $700.33K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-06-30 | $523.60K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-08-12 | $619.84K 10-Q/A · filed 2022-08-12 | $132.47K 10-Q · filed 2020-08-14 | $690.65K derived: sum of 3 quarters · filed 2022-08-12 | $775.47K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-03-31 | $96.25K 10-Q · filed 2021-05-21 | $167.06K derived: sum of 2 quarters · filed 2021-05-21 | $251.87K derived: sum of 3 quarters · filed 2021-05-21 | $80.23K derived: sum of 4 quarters · filed 2021-05-21 | |||
| 2019-12-31 | $70.81K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $155.62K derived: sum of 2 quarters · filed 2021-05-14 | -$16.02K derived: sum of 3 quarters · filed 2021-05-14 | $845.62K 10-K/A · filed 2021-05-14 | |||
| 2019-09-30 | $84.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$86.83K derived: sum of 2 quarters · filed 2020-11-16 | $774.81K 10-Q · filed 2020-11-16 | $1.46M derived: sum of 4 quarters · filed 2020-11-16 | |||
| 2019-06-30 | -$171.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $690.00K 10-Q · filed 2020-08-14 | $1.38M derived: sum of 3 quarters · filed 2020-08-14 | $1.38M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $861.64K 10-Q · filed 2020-05-15 | $1.55M derived: sum of 2 quarters · filed 2020-05-15 | $1.55M derived: sum of 3 quarters · filed 2020-05-15 | $1.55M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $690.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $690.00K derived: sum of 2 quarters · filed 2020-03-30 | $690.00K derived: sum of 3 quarters · filed 2020-03-30 | $690.00K 10-K · filed 2020-03-30 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | |||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |